bio-protparam 0.1.0

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (14) hide show
  1. data/.document +5 -0
  2. data/.travis.yml +12 -0
  3. data/Gemfile +9 -0
  4. data/LICENSE.txt +20 -0
  5. data/README.md +47 -0
  6. data/README.rdoc +48 -0
  7. data/Rakefile +42 -0
  8. data/VERSION +1 -0
  9. data/lib/bio-protparam.rb +12 -0
  10. data/lib/bio/util/protparam.rb +817 -0
  11. data/test/data/uniprot/p53_human.uniprot +1456 -0
  12. data/test/helper.rb +20 -0
  13. data/test/test_bio-protparam.rb +121 -0
  14. metadata +130 -0
data/test/data/uniprot/p53_human.uniprot ADDED
@@ -0,0 +1,1456 @@
1
+ ID P53_HUMAN STANDARD; PRT; 393 AA.
2
+ AC P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
3
+ AC Q16810; Q16811; Q16848; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8;
4
+ AC Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61;
5
+ DT 13-AUG-1987 (Rel. 05, Created)
6
+ DT 01-MAR-1989 (Rel. 10, Last sequence update)
7
+ DT 13-SEP-2005 (Rel. 48, Last annotation update)
8
+ DE Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53)
9
+ DE (Antigen NY-CO-13).
10
+ GN Name=TP53; Synonyms=P53;
11
+ OS Homo sapiens (Human).
12
+ OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
13
+ OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
14
+ OC Homo.
15
+ OX NCBI_TaxID=9606;
16
+ RN [1]
17
+ RP NUCLEOTIDE SEQUENCE.
18
+ RX MEDLINE=85230577; PubMed=4006916;
19
+ RA Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
20
+ RT "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
21
+ RT cells.";
22
+ RL EMBO J. 4:1251-1255(1985).
23
+ RN [2]
24
+ RP NUCLEOTIDE SEQUENCE.
25
+ RX MEDLINE=87064416; PubMed=2946935;
26
+ RA Lamb P., Crawford L.;
27
+ RT "Characterization of the human p53 gene.";
28
+ RL Mol. Cell. Biol. 6:1379-1385(1986).
29
+ RN [3]
30
+ RP NUCLEOTIDE SEQUENCE.
31
+ RX MEDLINE=85267676; PubMed=3894933;
32
+ RA Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
33
+ RT "Molecular cloning and in vitro expression of a cDNA clone for human
34
+ RT cellular tumor antigen p53.";
35
+ RL Mol. Cell. Biol. 5:1601-1610(1985).
36
+ RN [4]
37
+ RP NUCLEOTIDE SEQUENCE.
38
+ RX MEDLINE=87089826; PubMed=3025664;
39
+ RA Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
40
+ RA Rotter V.;
41
+ RT "Molecular basis for heterogeneity of the human p53 protein.";
42
+ RL Mol. Cell. Biol. 6:4650-4656(1986).
43
+ RN [5]
44
+ RP NUCLEOTIDE SEQUENCE.
45
+ RX MEDLINE=89108008; PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
46
+ RA Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
47
+ RA Georgiev G.P.;
48
+ RT "A variation in the structure of the protein-coding region of the
49
+ RT human p53 gene.";
50
+ RL Gene 70:245-252(1988).
51
+ RN [6]
52
+ RP NUCLEOTIDE SEQUENCE OF 101-393.
53
+ RX MEDLINE=85126934; PubMed=6396087;
54
+ RA Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
55
+ RA Benchimol S.;
56
+ RT "Isolation and characterization of a human p53 cDNA clone: expression
57
+ RT of the human p53 gene.";
58
+ RL EMBO J. 3:3257-3262(1984).
59
+ RN [7]
60
+ RP NUCLEOTIDE SEQUENCE, VARIANTS BURKITT'S LYMPHOMA, AND VARIANT ARG-72.
61
+ RX MEDLINE=92007731; PubMed=1915267;
62
+ RA Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
63
+ RT "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
64
+ RL EMBO J. 10:2879-2887(1991).
65
+ RN [8]
66
+ RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
67
+ RX MEDLINE=93303270; PubMed=8316628;
68
+ RA Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
69
+ RA Mirzayans R.;
70
+ RT "Isolation of two cell lines from a human malignant glioma specimen
71
+ RT differing in sensitivity to radiation and chemotherapeutic drugs.";
72
+ RL Radiat. Res. 134:349-354(1993).
73
+ RN [9]
74
+ RP NUCLEOTIDE SEQUENCE, AND VARIANT ARG-72.
75
+ RX MEDLINE=21264809; PubMed=11058590; DOI=10.1074/jbc.M007140200;
76
+ RA Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
77
+ RA Zevotek N.;
78
+ RT "Hyaluronidase induction of a WW domain-containing oxidoreductase that
79
+ RT enhances tumor necrosis factor cytotoxicity.";
80
+ RL J. Biol. Chem. 276:3361-3370(2001).
81
+ RN [10]
82
+ RP NUCLEOTIDE SEQUENCE.
83
+ RA Chumakov P.M., Almazov V.P., Jenkins J.R.;
84
+ RL Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
85
+ RN [11]
86
+ RP NUCLEOTIDE SEQUENCE.
87
+ RA Rozemuller E.H., Tilanus M.G.J.;
88
+ RT "P53 genomic sequence. Corrections and polymorphism.";
89
+ RL Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
90
+ RN [12]
91
+ RP NUCLEOTIDE SEQUENCE, AND VARIANTS SER-47; ARG-72; LYS-339 AND ALA-366.
92
+ RA Livingston R.J., Rieder M.J., Chung M.-W., Ritchie T.K., Olson A.N.,
93
+ RA Nguyen C.P., Gildersleeve H., Cassidy C.M., Johnson E.J.,
94
+ RA Swanson J.E., McFarland I., Yool B., Park C., Nickerson D.A.;
95
+ RT "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
96
+ RT of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
97
+ RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
98
+ RN [13]
99
+ RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
100
+ RX PubMed=11023613;
101
+ RA Anderson C.W., Allalunis-Turner M.J.;
102
+ RT "Human TP53 from the malignant glioma-derived cell lines M059J and
103
+ RT M059K has a cancer-associated mutation in exon 8.";
104
+ RL Radiat. Res. 154:473-476(2000).
105
+ RN [14]
106
+ RP NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72; HIS-273 AND SER-309.
107
+ RA Azuma K., Shichijo S., Itoh K.;
108
+ RT "Identification of a tumor-rejection antigen recognized by HLA-B46
109
+ RT restricted CTL.";
110
+ RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
111
+ RN [15]
112
+ RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-72 AND
113
+ RP ALA-278.
114
+ RC TISSUE=Kidney;
115
+ RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
116
+ RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
117
+ RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
118
+ RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
119
+ RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
120
+ RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
121
+ RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
122
+ RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
123
+ RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
124
+ RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
125
+ RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
126
+ RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
127
+ RA Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
128
+ RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
129
+ RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
130
+ RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
131
+ RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
132
+ RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
133
+ RT "Generation and initial analysis of more than 15,000 full-length human
134
+ RT and mouse cDNA sequences.";
135
+ RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
136
+ RN [16]
137
+ RP NUCLEOTIDE SEQUENCE OF 1-379, AND VARIANTS ARG-72 AND ASN-139.
138
+ RC TISSUE=Lung carcinoma;
139
+ RX PubMed=14660794; DOI=10.1073/pnas.2536558100;
140
+ RA Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
141
+ RA Varga J.L.;
142
+ RT "Inhibition of mutant p53 expression and growth of DMS-153 small cell
143
+ RT lung carcinoma by antagonists of growth hormone-releasing hormone and
144
+ RT bombesin.";
145
+ RL Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
146
+ RN [17]
147
+ RP NUCLEOTIDE SEQUENCE OF 126-185.
148
+ RA Pan X.L., Zhang A.H.;
149
+ RT "Study on the effect of tumor suppressor gene p53 in arsenism
150
+ RT patients.";
151
+ RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
152
+ RN [18]
153
+ RP NUCLEOTIDE SEQUENCE OF 261-298.
154
+ RC TISSUE=Blood;
155
+ RA Nimri L.F., Owais W., Momani E.;
156
+ RT "Detection of P53 gene mutations and serum p53 antibodies associated
157
+ RT with cigarette smoking.";
158
+ RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
159
+ RN [19]
160
+ RP NUCLEOTIDE SEQUENCE OF 262-306.
161
+ RC TISSUE=Ovarian adenocarcinoma;
162
+ RA Filippini G., Soldati G.;
163
+ RL Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
164
+ RN [20]
165
+ RP NUCLEOTIDE SEQUENCE OF 225-260.
166
+ RC TISSUE=Glial cell, and Glial tumor;
167
+ RA Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
168
+ RA Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
169
+ RT "Mutation detection utilizing a novel PCR approach for amplification
170
+ RT of the p53 gene from microdissected tissue: application to archival
171
+ RT tumor samples.";
172
+ RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
173
+ RN [21]
174
+ RP NUCLEOTIDE SEQUENCE OF 225-260.
175
+ RA Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
176
+ RA Lipsky P.E.;
177
+ RT "Bcl6 and P53 gene mutations in tonsillar B cells.";
178
+ RL Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
179
+ RN [22]
180
+ RP NUCLEOTIDE SEQUENCE OF 332-366.
181
+ RA Pinto E.M., Mendonca B.B., Latronico A.C.;
182
+ RT "Allelic variant in intron 9 of TP53 gene.";
183
+ RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
184
+ RN [23]
185
+ RP RNA-BINDING.
186
+ RX MEDLINE=91141509; PubMed=1705009;
187
+ RA Samad A., Carroll R.B.;
188
+ RT "The tumor suppressor p53 is bound to RNA by a stable covalent
189
+ RT linkage.";
190
+ RL Mol. Cell. Biol. 11:1598-1606(1991).
191
+ RN [24]
192
+ RP ALTERNATIVE SPLICING.
193
+ RX MEDLINE=96197761; PubMed=8632903;
194
+ RA Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
195
+ RA Gilbert D., Iggo R., Frebourg T.;
196
+ RT "The human tumour suppressor gene p53 is alternatively spliced in
197
+ RT normal cells.";
198
+ RL Oncogene 12:813-818(1996).
199
+ RN [25]
200
+ RP NUCLEAR LOCALIZATION SIGNAL.
201
+ RX MEDLINE=90191730; PubMed=2156209;
202
+ RA Addison C., Jenkins J.R., Sturzbecher H.-W.;
203
+ RT "The p53 nuclear localisation signal is structurally linked to a
204
+ RT p34cdc2 kinase motif.";
205
+ RL Oncogene 5:423-426(1990).
206
+ RN [26]
207
+ RP MINIMAL REPRESSION DOMAIN.
208
+ RX MEDLINE=21125692; PubMed=11007800; DOI=10.1074/jbc.M008231200;
209
+ RA Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
210
+ RT "p53 amino acids 339-346 represent the minimal p53 repression
211
+ RT domain.";
212
+ RL J. Biol. Chem. 276:1510-1515(2001).
213
+ RN [27]
214
+ RP INTERACTION WITH ING4.
215
+ RX MEDLINE=22635239; PubMed=12750254;
216
+ RA Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
217
+ RA Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
218
+ RA Harris C.C.;
219
+ RT "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
220
+ RL Cancer Res. 63:2373-2378(2003).
221
+ RN [28]
222
+ RP PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
223
+ RX MEDLINE=90280456; PubMed=2141171;
224
+ RA Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
225
+ RT "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
226
+ RL Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
227
+ RN [29]
228
+ RP DEPHOSPHORYLATION BY PP2A.
229
+ RX MEDLINE=91172186; PubMed=1848668;
230
+ RA Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
231
+ RT "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
232
+ RT by protein phosphatase 2A: inhibition by small-t antigen.";
233
+ RL Mol. Cell. Biol. 11:1996-2003(1991).
234
+ RN [30]
235
+ RP O-GLYCOSYLATION.
236
+ RX MEDLINE=96197773; PubMed=8632915;
237
+ RA Shaw P., Freeman J., Bovey R., Iggo R.;
238
+ RT "Regulation of specific DNA binding by p53: evidence for a role for O-
239
+ RT glycosylation and charged residues at the carboxy-terminus.";
240
+ RL Oncogene 12:921-930(1996).
241
+ RN [31]
242
+ RP PHOSPHORYLATION BY PRPK.
243
+ RX MEDLINE=21570176; PubMed=11546806; DOI=10.1074/jbc.M105669200;
244
+ RA Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
245
+ RA Shigemoto K., Hitsumoto Y., Nikawa J.-I., Enomoto Y.;
246
+ RT "Cloning and characterization of a p53-related protein kinase
247
+ RT expressed in interleukin-2-activated cytotoxic T-cells, epithelial
248
+ RT tumor cell lines, and the testes.";
249
+ RL J. Biol. Chem. 276:44003-44011(2001).
250
+ RN [32]
251
+ RP PHOSPHORYLATION SITE THR-18.
252
+ RX MEDLINE=20406546; PubMed=10951572; DOI=10.1038/sj.onc.1203709;
253
+ RA Lopez-Borges S., Lazo P.A.;
254
+ RT "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
255
+ RT 18 within the mdm-2 binding site of the p53 tumour suppressor
256
+ RT protein.";
257
+ RL Oncogene 19:3656-3664(2000).
258
+ RN [33]
259
+ RP IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
260
+ RX MEDLINE=21659718; PubMed=11706030; DOI=10.1074/jbc.M108535200;
261
+ RA Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
262
+ RT "Differential effect of ik3-1/cables on p53- and p73-induced cell
263
+ RT death.";
264
+ RL J. Biol. Chem. 277:2951-2957(2002).
265
+ RN [34]
266
+ RP PHOSPHORYLATION SITE THR-55, MUTAGENESIS OF THR-55, AND INTERACTION
267
+ RP WITH TAF1.
268
+ RX PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
269
+ RA Li H.-H., Li A.G., Sheppard H.M., Liu X.;
270
+ RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
271
+ RT for TAF1 in cell G1 progression.";
272
+ RL Mol. Cell 13:867-878(2004).
273
+ RN [35]
274
+ RP ACETYLATION SITE LYS-305.
275
+ RX MEDLINE=22726738; PubMed=12724314; DOI=10.1074/jbc.M212574200;
276
+ RA Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
277
+ RT "Identification and characterization of a novel p300-mediated p53
278
+ RT acetylation site, lysine 305.";
279
+ RL J. Biol. Chem. 278:25568-25576(2003).
280
+ RN [36]
281
+ RP ACETYLATION SITES LYS-373 AND LYS-382.
282
+ RX MEDLINE=20123976; PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
283
+ RA Abraham J., Kelly J., Thibault P., Benchimol S.;
284
+ RT "Post-translational modification of p53 protein in response to
285
+ RT ionizing radiation analyzed by mass spectrometry.";
286
+ RL J. Mol. Biol. 295:853-864(2000).
287
+ RN [37]
288
+ RP DEACETYLATION OF LYS-382 BY SIRT1.
289
+ RX MEDLINE=21526627; PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
290
+ RA Vaziri H., Dessain S.K., Ng Eaton E., Imai S.-I., Frye R.A.,
291
+ RA Pandita T.K., Guarente L., Weinberg R.A.;
292
+ RT "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
293
+ RL Cell 107:149-159(2001).
294
+ RN [38]
295
+ RP INTERACTION WITH HIPK2.
296
+ RX MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
297
+ RA Kim E.-J., Park J.-S., Um S.-J.;
298
+ RT "Identification and characterization of HIPK2 interacting with p73 and
299
+ RT modulating functions of the p53 family in vivo.";
300
+ RL J. Biol. Chem. 277:32020-32028(2002).
301
+ RN [39]
302
+ RP INTERACTION WITH HIPK2, PHOSPHORYLATION SITE SER-46, AND MUTAGENESIS
303
+ RP OF SER-46 AND LYS-382.
304
+ RX MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
305
+ RA Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
306
+ RA Will H., Schmitz M.L.;
307
+ RT "Regulation of p53 activity by its interaction with homeodomain-
308
+ RT interacting protein kinase-2.";
309
+ RL Nat. Cell Biol. 4:1-10(2002).
310
+ RN [40]
311
+ RP INTERACTION WITH HIPK2, AND PHOSPHORYLATION SITE SER-46.
312
+ RX MEDLINE=21638694; PubMed=11780126; DOI=10.1038/ncb714;
313
+ RA D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
314
+ RA Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
315
+ RA Fanciulli M., Appella E., Soddu S.;
316
+ RT "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
317
+ RT and mediates apoptosis.";
318
+ RL Nat. Cell Biol. 4:11-19(2002).
319
+ RN [41]
320
+ RP INTERACTION WITH P53DINP1.
321
+ RX MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
322
+ RA Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
323
+ RA Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
324
+ RT "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
325
+ RT partners in regulating p53 activity.";
326
+ RL J. Biol. Chem. 278:37722-37729(2003).
327
+ RN [42]
328
+ RP INTERACTION WITH HIPK1.
329
+ RX MEDLINE=22608637; PubMed=12702766; DOI=10.1073/pnas.0530308100;
330
+ RA Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
331
+ RA Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
332
+ RA Mak T.W., Thukral S.K.;
333
+ RT "Characterization of cells and gene-targeted mice deficient for the
334
+ RT p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
335
+ RL Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
336
+ RN [43]
337
+ RP INTERACTIONS WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
338
+ RX PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
339
+ RA An W., Kim J., Roeder R.G.;
340
+ RT "Ordered cooperative functions of PRMT1, p300, and CARM1 in
341
+ RT transcriptional activation by p53.";
342
+ RL Cell 117:735-748(2004).
343
+ RN [44]
344
+ RP NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
345
+ RX MEDLINE=22825602; PubMed=12944468;
346
+ RX DOI=10.1128/MCB.23.18.6396-6405.2003;
347
+ RA O'Keefe K., Li H., Zhang Y.;
348
+ RT "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
349
+ RT cytoplasmic degradation but not ubiquitination.";
350
+ RL Mol. Cell. Biol. 23:6396-6405(2003).
351
+ RN [45]
352
+ RP REVIEW ON ZINC-BINDING PROPERTIES.
353
+ RX MEDLINE=21438235; PubMed=11554448; DOI=10.1089/15230860152542961;
354
+ RA Hainaut P., Mann K.;
355
+ RT "Zinc binding and redox control of p53 structure and function.";
356
+ RL Antioxid. Redox Signal. 3:611-623(2001).
357
+ RN [46]
358
+ RP STRUCTURE BY NMR OF 319-360.
359
+ RX MEDLINE=94294808; PubMed=8023159;
360
+ RA Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
361
+ RA Appella E., Gronenborn A.M.;
362
+ RT "High-resolution structure of the oligomerization domain of p53 by
363
+ RT multidimensional NMR.";
364
+ RL Science 265:386-391(1994).
365
+ RN [47]
366
+ RP STRUCTURE BY NMR OF 325-355.
367
+ RX MEDLINE=95292092; PubMed=7773777;
368
+ RA Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
369
+ RT "Solution structure of the tetrameric minimum transforming domain of
370
+ RT p53.";
371
+ RL Nat. Struct. Biol. 1:877-890(1994).
372
+ RN [48]
373
+ RP STRUCTURE BY NMR OF 326-354.
374
+ RX MEDLINE=98026899; PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
375
+ RA McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
376
+ RA Halazonetis T.D.;
377
+ RT "Hydrophobic side-chain size is a determinant of the three-dimensional
378
+ RT structure of the p53 oligomerization domain.";
379
+ RL EMBO J. 16:6230-6236(1997).
380
+ RN [49]
381
+ RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
382
+ RX MEDLINE=94294806; PubMed=8023157;
383
+ RA Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
384
+ RT "Crystal structure of a p53 tumor suppressor-DNA complex:
385
+ RT understanding tumorigenic mutations.";
386
+ RL Science 265:346-355(1994).
387
+ RN [50]
388
+ RP X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
389
+ RX MEDLINE=95184011; PubMed=7878469;
390
+ RA Jeffrey P.D., Gorina S., Pavletich N.P.;
391
+ RT "Crystal structure of the tetramerization domain of the p53 tumor
392
+ RT suppressor at 1.7 angstroms.";
393
+ RL Science 267:1498-1502(1995).
394
+ RN [51]
395
+ RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
396
+ RX MEDLINE=97081050; PubMed=8875929; DOI=10.1126/science.274.5289.948;
397
+ RA Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
398
+ RA Levine A.J., Pavletich N.P.;
399
+ RT "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
400
+ RT transactivation domain.";
401
+ RL Science 274:948-953(1996).
402
+ RN [52]
403
+ RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
404
+ RX MEDLINE=97035414; PubMed=8875926; DOI=10.1126/science.274.5289.1001;
405
+ RA Gorina S., Pavletich N.P.;
406
+ RT "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
407
+ RT domains of 53BP2.";
408
+ RL Science 274:1001-1005(1996).
409
+ RN [53]
410
+ RP REVIEW.
411
+ RX MEDLINE=94090335; PubMed=8266092;
412
+ RA Harris C.C.;
413
+ RT "p53: at the crossroads of molecular carcinogenesis and risk
414
+ RT assessment.";
415
+ RL Science 262:1980-1981(1993).
416
+ RN [54]
417
+ RP REVIEW ON VARIANTS.
418
+ RX MEDLINE=91289156; PubMed=1905840;
419
+ RA Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
420
+ RT "p53 mutations in human cancers.";
421
+ RL Science 253:49-53(1991).
422
+ RN [55]
423
+ RP REVIEW ON VARIANTS.
424
+ RX MEDLINE=96271983; PubMed=8829653;
425
+ RX DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
426
+ RA de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
427
+ RA Liao D., Soussi T., Kovach J.S., Sommer S.S.;
428
+ RT "Database of mutations in the p53 and APC tumor suppressor genes
429
+ RT designed to facilitate molecular epidemiological analyses.";
430
+ RL Hum. Mutat. 7:202-213(1996).
431
+ RN [56]
432
+ RP VARIANT ARG-72.
433
+ RX MEDLINE=91153807; PubMed=1999338; DOI=10.1007/BF00201836;
434
+ RA Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
435
+ RT "Characterization of a frequent polymorphism in the coding sequence of
436
+ RT the Tp53 gene in colonic cancer patients and a control population.";
437
+ RL Hum. Genet. 86:369-370(1991).
438
+ RN [57]
439
+ RP VARIANT LFS THR-133.
440
+ RX MEDLINE=92034774; PubMed=1933902;
441
+ RA Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
442
+ RT "A germ line mutation in exon 5 of the p53 gene in an extended cancer
443
+ RT family.";
444
+ RL Cancer Res. 51:6385-6387(1991).
445
+ RN [58]
446
+ RP VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
447
+ RX MEDLINE=91057657; PubMed=1978757;
448
+ RA Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
449
+ RA Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
450
+ RA Friend S.H.;
451
+ RT "Germ line p53 mutations in a familial syndrome of breast cancer,
452
+ RT sarcomas, and other neoplasms.";
453
+ RL Science 250:1233-1238(1990).
454
+ RN [59]
455
+ RP VARIANT LFS ASP-245.
456
+ RX MEDLINE=91080929; PubMed=2259385; DOI=10.1038/348747a0;
457
+ RA Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
458
+ RT "Germ-line transmission of a mutated p53 gene in a cancer-prone family
459
+ RT with Li-Fraumeni syndrome.";
460
+ RL Nature 348:747-749(1990).
461
+ RN [60]
462
+ RP VARIANT LFS LEU-272.
463
+ RX MEDLINE=92147883; PubMed=1737852;
464
+ RA Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
465
+ RA Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
466
+ RA Knutsen T., Minna J.D.;
467
+ RT "Hereditary and acquired p53 gene mutations in childhood acute
468
+ RT lymphoblastic leukemia.";
469
+ RL J. Clin. Invest. 89:640-647(1992).
470
+ RN [61]
471
+ RP VARIANTS LFS HIS-273 AND VAL-325.
472
+ RX MEDLINE=92228023; PubMed=1565144;
473
+ RA Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
474
+ RA Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
475
+ RA Strong L.C.;
476
+ RT "Germline mutations of the p53 tumor-suppressor gene in children and
477
+ RT young adults with second malignant neoplasms.";
478
+ RL N. Engl. J. Med. 326:1309-1315(1992).
479
+ RN [62]
480
+ RP VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285.
481
+ RX MEDLINE=90295284; PubMed=1694291;
482
+ RA Bartek J., Iggo R., Gannon J., Lane D.P.;
483
+ RT "Genetic and immunochemical analysis of mutant p53 in human breast
484
+ RT cancer cell lines.";
485
+ RL Oncogene 5:893-899(1990).
486
+ RN [63]
487
+ RP VARIANTS COLON TUMORS PHE-241 AND HIS-273.
488
+ RX MEDLINE=91017544; PubMed=1699228;
489
+ RA Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
490
+ RA Gannon J.V., Lane D.P.;
491
+ RT "p53 mutations in colorectal cancer.";
492
+ RL Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
493
+ RN [64]
494
+ RP VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND
495
+ RP SER-278.
496
+ RX MEDLINE=91088630; PubMed=2263646;
497
+ RA Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
498
+ RT "Frequent mutation of the p53 gene in human esophageal cancer.";
499
+ RL Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
500
+ RN [65]
501
+ RP VARIANTS COLORECTAL CANCER MUTATIONS.
502
+ RX MEDLINE=91282784; PubMed=1647768;
503
+ RA Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
504
+ RA Wakui A., Yamazaki T.;
505
+ RT "Mutations of the P53 gene, including an intronic point mutation, in
506
+ RT colorectal tumors.";
507
+ RL Biochem. Biophys. Res. Commun. 177:901-906(1991).
508
+ RN [66]
509
+ RP VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND
510
+ RP HIS-273.
511
+ RX MEDLINE=91330175; PubMed=1868473;
512
+ RA Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
513
+ RA Roth J.A.;
514
+ RT "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
515
+ RL Cancer Res. 51:4495-4499(1991).
516
+ RN [67]
517
+ RP VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA.
518
+ RX MEDLINE=91187113; PubMed=1849234; DOI=10.1038/350427a0;
519
+ RA Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
520
+ RT "Mutational hotspot in the p53 gene in human hepatocellular
521
+ RT carcinomas.";
522
+ RL Nature 350:427-428(1991).
523
+ RN [68]
524
+ RP VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA.
525
+ RX MEDLINE=91187114; PubMed=1672732; DOI=10.1038/350429a0;
526
+ RA Bressac B., Kew M., Wands J., Ozturk M.;
527
+ RT "Selective G to T mutations of p53 gene in hepatocellular carcinoma
528
+ RT from southern Africa.";
529
+ RL Nature 350:429-431(1991).
530
+ RN [69]
531
+ RP VARIANTS HNSCC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
532
+ RX MEDLINE=93007999; PubMed=1394225;
533
+ RA Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
534
+ RA Casey G.;
535
+ RT "Frequent p53 mutations in head and neck cancer.";
536
+ RL Cancer Res. 52:5997-6000(1992).
537
+ RN [70]
538
+ RP VARIANTS ANOGENITAL CARCINOMAS.
539
+ RX MEDLINE=93010989; PubMed=1327751;
540
+ RA Crook T., Vousden K.H.;
541
+ RT "Properties of p53 mutations detected in primary and secondary
542
+ RT cervical cancers suggest mechanisms of metastasis and involvement of
543
+ RT environmental carcinogens.";
544
+ RL EMBO J. 11:3935-3940(1992).
545
+ RN [71]
546
+ RP VARIANTS ORAL SQUAMOUS CELL CARCINOMA CYS-205; GLU-281 AND LYS-285.
547
+ RX MEDLINE=93093790; PubMed=1459726;
548
+ RA Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
549
+ RA Yamamoto H., Tsuchida N.;
550
+ RT "The p53 tumor-suppressor gene and ras oncogene mutations in oral
551
+ RT squamous-cell carcinoma.";
552
+ RL Int. J. Cancer 52:867-872(1992).
553
+ RN [72]
554
+ RP VARIANT PRO-HIS-PRO-178 INS.
555
+ RX MEDLINE=93265016; PubMed=1303181;
556
+ RA Bhatia K., Guiterrez M.I., Magrath I.T.;
557
+ RT "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
558
+ RL Hum. Mol. Genet. 1:207-208(1992).
559
+ RN [73]
560
+ RP VARIANTS BURKITT'S LYMPHOMAS.
561
+ RX MEDLINE=93064692; PubMed=1437144;
562
+ RA Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
563
+ RA Appella E., May P.;
564
+ RT "p53 mutations in Raji cells: characterization and localization
565
+ RT relative to other Burkitt's lymphomas.";
566
+ RL Oncogene 7:2161-2167(1992).
567
+ RN [74]
568
+ RP VARIANT NASOPHARYNGEAL CARCINOMA THR-280.
569
+ RX MEDLINE=92335329; PubMed=1631151;
570
+ RA Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Cao Y.,
571
+ RA Yao K.-T., Colburn N.H.;
572
+ RT "An infrequent point mutation of the p53 gene in human nasopharyngeal
573
+ RT carcinoma.";
574
+ RL Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
575
+ RN [75]
576
+ RP VARIANTS HNSCC.
577
+ RX MEDLINE=93235942; PubMed=7682763;
578
+ RA Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
579
+ RT "p53 alterations in human squamous cell carcinomas and carcinoma cell
580
+ RT lines.";
581
+ RL Am. J. Pathol. 142:1131-1139(1993).
582
+ RN [76]
583
+ RP VARIANTS HNSCC.
584
+ RX MEDLINE=94006220; PubMed=8402617;
585
+ RA Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
586
+ RA Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
587
+ RT "The incidence of p53 mutations increases with progression of head and
588
+ RT neck cancer.";
589
+ RL Cancer Res. 53:4477-4480(1993).
590
+ RN [77]
591
+ RP VARIANTS COLON TUMORS.
592
+ RX MEDLINE=93330562; PubMed=8336944;
593
+ RA Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
594
+ RT "Efficient screening of p53 mutations by denaturing gradient gel
595
+ RT electrophoresis in colorectal tumors.";
596
+ RL Oncogene 8:2213-2220(1993).
597
+ RN [78]
598
+ RP CHARACTERIZATION OF VARIANT ALA-143.
599
+ RX MEDLINE=94283378; PubMed=8013454;
600
+ RA Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
601
+ RT "A temperature-sensitive mutant of human p53.";
602
+ RL EMBO J. 13:2535-2544(1994).
603
+ RN [79]
604
+ RP VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
605
+ RX MEDLINE=95193787; PubMed=7887414;
606
+ RA Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
607
+ RA Fraumeni J.F. Jr., Li F.P., Friend S.H.;
608
+ RT "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
609
+ RL Am. J. Hum. Genet. 56:608-615(1995).
610
+ RN [80]
611
+ RP VARIANT LFS HIS-175.
612
+ RX MEDLINE=96423319; PubMed=8825920;
613
+ RA Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
614
+ RA Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
615
+ RA Evans D.G.R.;
616
+ RT "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
617
+ RT 175 mutation in TP53.";
618
+ RL J. Med. Genet. 32:942-945(1995).
619
+ RN [81]
620
+ RP VARIANTS ESOPHAGEAL ADENOCARCINOMA PHE-176; SER-245; TRP-248; TRP-282
621
+ RP AND GLN-286.
622
+ RX MEDLINE=96233927; PubMed=8829627;
623
+ RX DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
624
+ RA Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
625
+ RA Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
626
+ RT "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
627
+ RL Hum. Mutat. 7:109-113(1996).
628
+ RN [82]
629
+ RP VARIANTS COLORECTAL TUMORS.
630
+ RX MEDLINE=97255965; PubMed=9101296;
631
+ RX DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
632
+ RA Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
633
+ RA Zeuthen J.;
634
+ RT "Single-step DGGE-based mutation scanning of the p53 gene: application
635
+ RT to genetic diagnosis of colorectal cancer.";
636
+ RL Hum. Mutat. 9:348-355(1997).
637
+ RN [83]
638
+ RP VARIANT COLORECTAL CARCINOMA ILE-157.
639
+ RX MEDLINE=98080146; PubMed=9419979; DOI=10.1038/sj.onc.1201668;
640
+ RA Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
641
+ RA Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
642
+ RA Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
643
+ RT "Drastic genetic instability of tumors and normal tissues in Turcot
644
+ RT syndrome.";
645
+ RL Oncogene 15:2877-2881(1997).
646
+ RN [84]
647
+ RP VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
648
+ RP AND SER-278.
649
+ RX MEDLINE=98111377; PubMed=9450901;
650
+ RX DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
651
+ RA van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
652
+ RA Raubenheimer E.J.;
653
+ RT "Detection of p53 gene mutations in oral squamous cell carcinomas of a
654
+ RT black African population sample.";
655
+ RL Hum. Mutat. 11:39-44(1998).
656
+ RN [85]
657
+ RP VARIANT NONCLASSICAL LFS CYS-337.
658
+ RX MEDLINE=98112421; PubMed=9452042;
659
+ RA Luca J.W., Strong L.C., Hansen M.F.;
660
+ RT "A germline missense mutation R337C in exon 10 of the human p53
661
+ RT gene.";
662
+ RL Hum. Mutat. Suppl. 1:S58-S61(1998).
663
+ RN [86]
664
+ RP VARIANT LFS ILE-292.
665
+ RX MEDLINE=99414637; PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
666
+ RA Gueran S., Tunca Y., Imirzalioglu N.;
667
+ RT "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
668
+ RT a Li-Fraumeni syndrome family.";
669
+ RL Cancer Genet. Cytogenet. 113:145-151(1999).
670
+ RN [87]
671
+ RP INVOLVEMENT IN CHOROID PLEXUS PAPILLOMA.
672
+ RX MEDLINE=22079076; PubMed=12085209; DOI=10.1038/sj/bjc/6600269;
673
+ RA Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
674
+ RA Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
675
+ RT "Investigations on a clinically and functionally unusual and novel
676
+ RT germline p53 mutation.";
677
+ RL Br. J. Cancer 86:1592-1596(2002).
678
+ CC -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
679
+ CC growth arrest or apoptosis depending on the physiological
680
+ CC circumstances and cell type. Involved in cell cycle regulation as
681
+ CC a trans-activator that acts to negatively regulate cell division
682
+ CC by controlling a set of genes required for this process. One of
683
+ CC the activated genes is an inhibitor of cyclin-dependent kinases.
684
+ CC Apoptosis induction seems to be mediated either by stimulation of
685
+ CC BAX and FAS antigen expression, or by repression of Bcl-2
686
+ CC expression.
687
+ CC -!- COFACTOR: Binds 1 zinc ion per subunit.
688
+ CC -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
689
+ CC consisiting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
690
+ CC a homotetramer. Interacts with histone acetyltransferases EP300
691
+ CC and methyltransferases HRMT1L2 and CARM1, and recruits them to
692
+ CC promoters. In vitro, the interaction of TP53 with cancer-
693
+ CC associated/HPV (E6) viral proteins leads to ubiquitination and
694
+ CC degradation of TP53 giving a possible model for cell growth
695
+ CC regulation. This complex formation requires an additional factor,
696
+ CC E6-AP, which stably associates with TP53 in the presence of E6. C-
697
+ CC terminus interacts with TAF1, when TAF1 is part of the TFIID
698
+ CC complex. Interacts with ING4 and this interaction may be indirect.
699
+ CC Found in a complex with CABLES1 and TP73. Interacts with HIPK1,
700
+ CC HIPK2, and P53DINP1.
701
+ CC -!- INTERACTION:
702
+ CC Q8TDN4:CABLES1; NbExp=1; IntAct=EBI-366083, EBI-604615;
703
+ CC Q9ESJ1:Cables1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-604411;
704
+ CC Q92793:CREBBP; NbExp=3; IntAct=EBI-366083, EBI-81215;
705
+ CC P42858:HD; NbExp=2; IntAct=EBI-366083, EBI-466029;
706
+ CC P09429:HMGB1; NbExp=1; IntAct=EBI-366083, EBI-389432;
707
+ CC P56273:MDM2 (xeno); NbExp=1; IntAct=EBI-366083, EBI-541233;
708
+ CC Q00987:MDM2; NbExp=1; IntAct=EBI-366083, EBI-389668;
709
+ CC P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579;
710
+ CC P06748-1:NPM1; NbExp=1; IntAct=EBI-366083, EBI-354150;
711
+ CC Q06609:RAD51; NbExp=1; IntAct=EBI-366083, EBI-297202;
712
+ CC Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
713
+ CC P20226:TBP; NbExp=1; IntAct=EBI-366083, EBI-355371;
714
+ CC Q7Z6Z7:UREB1; NbExp=2; IntAct=EBI-366083, EBI-625934;
715
+ CC -!- SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
716
+ CC -!- ALTERNATIVE PRODUCTS:
717
+ CC Event=Alternative splicing; Named isoforms=2;
718
+ CC Name=1;
719
+ CC IsoId=P04637-1; Sequence=Displayed;
720
+ CC Name=2; Synonyms=I9RET;
721
+ CC IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
722
+ CC Note=Seems to be non-functional. Expressed in quiescent
723
+ CC lymphocytes;
724
+ CC -!- DOMAIN: The nuclear export signal acts as a transcriptional
725
+ CC repression domain.
726
+ CC -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
727
+ CC transcriptional activity. Deacetylation of Lys-382 by SIRT1
728
+ CC impairs its ability to induce proapoptotic program and modulate
729
+ CC cell senescence.
730
+ CC -!- PTM: Phosphorylated. Phosphorylation on Ser residues mediates
731
+ CC transcriptional activation. Phosphorylated by HIPK1 (By
732
+ CC similarity). Phosphorylated on Thr-18 by VRK1, which may prevent
733
+ CC the interaction with MDM2. Phosphorylated on Thr-55 by TAF1, which
734
+ CC promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by
735
+ CC HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required
736
+ CC for acetylation by CREBBP.
737
+ CC -!- PTM: Dephosphorylated by PP2A. SV40 small T antigen inhibits the
738
+ CC dephosphorylation by the AC form of PP2A.
739
+ CC -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
740
+ CC in EB-1 cell line.
741
+ CC -!- DISEASE: TP53 is found in increased amounts in a wide variety of
742
+ CC transformed cells. TP53 is frequently mutated or inactivated in
743
+ CC about 60% of cancers.
744
+ CC -!- DISEASE: Defects in TP53 are involved in esophageal squamous cell
745
+ CC carcinoma (ESCC) [MIM:133239]. ESCC is a tumor of the esophagus.
746
+ CC -!- DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS)
747
+ CC [MIM:151623]. LFS is an autosomal dominant familial cancer
748
+ CC syndrome that in its classic form is defined by the existence of
749
+ CC both a proband with a sarcoma and two other first-degree relatives
750
+ CC with a cancer by age 45 years. In these families the affected
751
+ CC relatives develop a diverse set of malignancies at unusually early
752
+ CC ages. The spectrum of cancers in LFS includes breast carcinomas,
753
+ CC soft-tissue sarcomas, brain tumors, osteosarcoma, leukemia and
754
+ CC adreno-cortical carcinoma. Other possible component tumors of LFS
755
+ CC are melanoma, gonadal cell tumors and carcinomas of the lung,
756
+ CC pancreas and prostate.
757
+ CC -!- DISEASE: Defects in TP53 are found in Barrett metaplasia; also
758
+ CC known as Barrett esophagus. It is a condition in which the
759
+ CC normally stratified squamous epithelium of the lower esophagus is
760
+ CC replaced by a metaplastic columnar epithelium. The condition
761
+ CC develops as a complication in approximately 10% of patients with
762
+ CC chronic gastroesophageal reflux disease and predisposes to the
763
+ CC development of esophageal adenocarcinoma.
764
+ CC -!- DISEASE: Defects in TP53 are involved in head and neck squamous
765
+ CC cell carcinomas (HNSCC) [MIM:275355].
766
+ CC -!- DISEASE: Defects in TP53 are involved in oral squamous cell
767
+ CC carcinoma (OSCC). Cigarette smoke is a prime mutagenic agent in
768
+ CC cancer of the aerodigestive tract.
769
+ CC -!- DISEASE: Defects in TP53 are a cause of lung cancer [MIM:211980].
770
+ CC -!- DISEASE: Defects in TP53 are a cause of choroid plexus papilloma
771
+ CC [MIM:260500]. Choroid plexus papilloma is a slow-growing benign
772
+ CC tumor of the choroid plexus that often invades the leptomeninges.
773
+ CC In children it is usually in a lateral ventricle but in adults it
774
+ CC is more often in the fourth ventricle. Hydrocephalus is common,
775
+ CC either from obstruction or from tumor secretion of cerebrospinal
776
+ CC fluid. If it undergoes malignant transformation it is called a
777
+ CC choroid plexus carcinoma. Primary choroid plexus tumors are rare
778
+ CC and usually occur in early childhood.
779
+ CC -!- SIMILARITY: Belongs to the p53 family.
780
+ CC -!- DATABASE: NAME=IARC TP53 mutation database;
781
+ CC NOTE=IARC db of somatic p53 mutations;
782
+ CC WWW="http://www.iarc.fr/p53/".
783
+ CC -!- DATABASE: NAME=Tokyo p53;
784
+ CC NOTE=University of Tokyo db of p53 mutations;
785
+ CC WWW="http://p53.genome.ad.jp/".
786
+ CC -!- DATABASE: NAME=p53 web site at the Institut Curie;
787
+ CC WWW="http://p53.curie.fr/".
788
+ CC -!- DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;
789
+ CC WWW="http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html".
790
+ CC --------------------------------------------------------------------------
791
+ CC This Swiss-Prot entry is copyright. It is produced through a collaboration
792
+ CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
793
+ CC the European Bioinformatics Institute. There are no restrictions on its
794
+ CC use as long as its content is in no way modified and this statement is not
795
+ CC removed.
796
+ CC --------------------------------------------------------------------------
797
+ DR EMBL; X02469; CAA26306.1; -; mRNA.
798
+ DR EMBL; M13121; AAA59987.1; -; Genomic_DNA.
799
+ DR EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
800
+ DR EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
801
+ DR EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
802
+ DR EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
803
+ DR EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
804
+ DR EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
805
+ DR EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
806
+ DR EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
807
+ DR EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
808
+ DR EMBL; K03199; AAA59989.1; -; mRNA.
809
+ DR EMBL; M14694; AAA61211.1; -; mRNA.
810
+ DR EMBL; M14695; AAA61212.1; -; mRNA.
811
+ DR EMBL; M22898; AAA59988.1; -; Genomic_DNA.
812
+ DR EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
813
+ DR EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
814
+ DR EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
815
+ DR EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
816
+ DR EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
817
+ DR EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
818
+ DR EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
819
+ DR EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
820
+ DR EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
821
+ DR EMBL; X01405; CAA25652.1; -; mRNA.
822
+ DR EMBL; X60011; CAA42626.1; -; mRNA.
823
+ DR EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
824
+ DR EMBL; X60013; CAA42628.1; -; mRNA.
825
+ DR EMBL; X60014; CAA42629.1; -; mRNA.
826
+ DR EMBL; X60015; CAA42630.1; -; mRNA.
827
+ DR EMBL; X60016; CAA42631.1; -; mRNA.
828
+ DR EMBL; X60017; CAA42632.1; -; mRNA.
829
+ DR EMBL; X60018; CAA42633.1; -; mRNA.
830
+ DR EMBL; X60019; CAA42634.1; -; mRNA.
831
+ DR EMBL; X60020; CAA42635.1; -; mRNA.
832
+ DR EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
833
+ DR EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
834
+ DR EMBL; AF307851; AAG28785.1; -; mRNA.
835
+ DR EMBL; X54156; CAA38095.1; -; Genomic_DNA.
836
+ DR EMBL; U94788; AAC12971.1; -; Genomic_DNA.
837
+ DR EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
838
+ DR EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
839
+ DR EMBL; AB082923; BAC16799.1; -; mRNA.
840
+ DR EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
841
+ DR EMBL; BC003596; AAH03596.1; -; mRNA.
842
+ DR EMBL; AY429684; AAR10356.1; -; mRNA.
843
+ DR EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
844
+ DR EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
845
+ DR EMBL; U63714; AAB39322.1; -; Genomic_DNA.
846
+ DR EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
847
+ DR EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
848
+ DR EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
849
+ DR EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
850
+ DR EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
851
+ DR EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
852
+ DR EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
853
+ DR EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
854
+ DR EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
855
+ DR EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
856
+ DR EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
857
+ DR EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
858
+ DR EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
859
+ DR EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
860
+ DR EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
861
+ DR EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
862
+ DR EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
863
+ DR EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
864
+ DR EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
865
+ DR EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
866
+ DR EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
867
+ DR EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
868
+ DR EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
869
+ DR EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
870
+ DR PIR; A25224; DNHU53.
871
+ DR PDB; 1A1U; NMR; A/C=324-358.
872
+ DR PDB; 1AIE; X-ray; @=326-356.
873
+ DR PDB; 1C26; X-ray; A=325-356.
874
+ DR PDB; 1DT7; NMR; X/Y=367-388.
875
+ DR PDB; 1GZH; X-ray; A/C=-.
876
+ DR PDB; 1H26; X-ray; E=376-386.
877
+ DR PDB; 1HS5; NMR; A/B=324-357.
878
+ DR PDB; 1KZY; X-ray; A/B=95-289.
879
+ DR PDB; 1OLG; NMR; A/B/C/D=319-360.
880
+ DR PDB; 1OLH; NMR; A/B/C/D=319-360.
881
+ DR PDB; 1PES; NMR; A/B/C/D=325-355.
882
+ DR PDB; 1PET; NMR; A/B/C/D=325-355.
883
+ DR PDB; 1SAE; NMR; A/B/C/D=319-360.
884
+ DR PDB; 1SAF; NMR; A/B/C/D=319-360.
885
+ DR PDB; 1SAG; NMR; A/B/C/D=319-360.
886
+ DR PDB; 1SAH; NMR; A/B/C/D=319-360.
887
+ DR PDB; 1SAI; NMR; A/B/C/D=319-360.
888
+ DR PDB; 1SAJ; NMR; A/B/C/D=319-360.
889
+ DR PDB; 1SAK; NMR; A/B/C/D=319-360.
890
+ DR PDB; 1SAL; NMR; A/B/C/D=319-360.
891
+ DR PDB; 1TSR; X-ray; A/B/C=94-312.
892
+ DR PDB; 1TUP; X-ray; A/B/C=94-312.
893
+ DR PDB; 1UOL; X-ray; A/B=94-312.
894
+ DR PDB; 1YCQ; X-ray; B=13-29.
895
+ DR PDB; 1YCR; X-ray; B=15-29.
896
+ DR PDB; 1YCS; X-ray; A=94-292.
897
+ DR PDB; 2BIM; X-ray; A/B=94-312.
898
+ DR PDB; 2BIN; X-ray; A=94-312.
899
+ DR PDB; 2BIO; X-ray; A=94-312.
900
+ DR PDB; 2BIP; X-ray; A=94-312.
901
+ DR PDB; 2BIQ; X-ray; A=94-312.
902
+ DR PDB; 3SAK; NMR; A/B/C/D=319-360.
903
+ DR IntAct; P04637; -.
904
+ DR TRANSFAC; T00671; -.
905
+ DR SWISS-2DPAGE; P04637; HUMAN.
906
+ DR Ensembl; ENSG00000141510; Homo sapiens.
907
+ DR HGNC; HGNC:11998; TP53.
908
+ DR H-InvDB; HIX0013510; -.
909
+ DR Reactome; P04637; -.
910
+ DR MIM; 191170; -.
911
+ DR MIM; 133239; -.
912
+ DR MIM; 151623; -.
913
+ DR MIM; 275355; -.
914
+ DR MIM; 211980; -.
915
+ DR MIM; 260500; -.
916
+ DR GO; GO:0005739; C:mitochondrion; IDA.
917
+ DR GO; GO:0005730; C:nucleolus; IDA.
918
+ DR GO; GO:0005524; F:ATP binding; IDA.
919
+ DR GO; GO:0005507; F:copper ion binding; IDA.
920
+ DR GO; GO:0000739; F:DNA strand annealing activity; IDA.
921
+ DR GO; GO:0004518; F:nuclease activity; TAS.
922
+ DR GO; GO:0005515; F:protein binding; IPI.
923
+ DR GO; GO:0046982; F:protein heterodimerization activity; IPI.
924
+ DR GO; GO:0003700; F:transcription factor activity; IDA.
925
+ DR GO; GO:0008270; F:zinc ion binding; TAS.
926
+ DR GO; GO:0006915; P:apoptosis; IDA.
927
+ DR GO; GO:0006284; P:base-excision repair; TAS.
928
+ DR GO; GO:0008635; P:caspase activation via cytochrome c; IDA.
929
+ DR GO; GO:0007569; P:cell aging; IMP.
930
+ DR GO; GO:0007050; P:cell cycle arrest; TAS.
931
+ DR GO; GO:0000075; P:cell cycle checkpoint; TAS.
932
+ DR GO; GO:0030154; P:cell differentiation; TAS.
933
+ DR GO; GO:0008283; P:cell proliferation; TAS.
934
+ DR GO; GO:0008630; P:DNA damage response, signal transduction re...; TAS.
935
+ DR GO; GO:0006310; P:DNA recombination; TAS.
936
+ DR GO; GO:0008628; P:induction of apoptosis by hormones; TAS.
937
+ DR GO; GO:0030308; P:negative regulation of cell growth; IMP.
938
+ DR GO; GO:0051097; P:negative regulation of helicase activity; TAS.
939
+ DR GO; GO:0006289; P:nucleotide-excision repair; IMP.
940
+ DR GO; GO:0051262; P:protein tetramerization; TAS.
941
+ DR GO; GO:0046902; P:regulation of mitochondrial membrane permea...; TAS.
942
+ DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IDA.
943
+ DR InterPro; IPR002117; P53.
944
+ DR InterPro; IPR011615; P53_DNA_bd.
945
+ DR InterPro; IPR012346; P53_RUNT_DNA_bd.
946
+ DR InterPro; IPR010991; p53_tetrameristn.
947
+ DR Pfam; PF00870; P53; 1.
948
+ DR Pfam; PF07710; P53_tetramer; 1.
949
+ DR PRINTS; PR00386; P53SUPPRESSR.
950
+ DR ProDom; PD002681; P53; 1.
951
+ DR PROSITE; PS00348; P53; 1.
952
+ KW 3D-structure; Acetylation; Activator; Alternative splicing;
953
+ KW Anti-oncogene; Apoptosis; Cell cycle; Disease mutation; DNA-binding;
954
+ KW Glycoprotein; Li-Fraumeni syndrome; Metal-binding; Nuclear protein;
955
+ KW Phosphorylation; Polymorphism; Transcription;
956
+ KW Transcription regulation; Zinc.
957
+ FT DNA_BIND 102 292
958
+ FT REGION 1 83 Interaction with HRMT1L2.
959
+ FT REGION 1 44 Transcription activation (acidic).
960
+ FT REGION 100 370 Interaction with HIPK1 (By similarity).
961
+ FT REGION 116 292 Interaction with AXIN1 (By similarity).
962
+ FT REGION 241 248 Interacts with the 53BP2 SH3 domain.
963
+ FT REGION 300 393 Interaction with CARM1.
964
+ FT REGION 319 360 Interaction with HIPK2.
965
+ FT REGION 325 356 Oligomerization.
966
+ FT REGION 368 387 Basic (repression of DNA-binding).
967
+ FT MOTIF 305 321 Bipartite nuclear localization signal.
968
+ FT MOTIF 339 350 Nuclear export signal.
969
+ FT METAL 176 176 Zinc.
970
+ FT METAL 179 179 Zinc.
971
+ FT METAL 238 238 Zinc.
972
+ FT METAL 242 242 Zinc.
973
+ FT BINDING 392 392 5'-phospho-RNA (covalent).
974
+ FT MOD_RES 15 15 Phosphoserine (by PRPK).
975
+ FT MOD_RES 18 18 Phosphothreonine (by VRK1).
976
+ FT MOD_RES 46 46 Phosphoserine (by HIPK2).
977
+ FT MOD_RES 55 55 Phosphothreonine (by TAF1).
978
+ FT MOD_RES 305 305 N6-acetyllysine.
979
+ FT MOD_RES 315 315 Phosphoserine (by CDC2).
980
+ FT MOD_RES 373 373 N6-acetyllysine.
981
+ FT MOD_RES 382 382 N6-acetyllysine.
982
+ FT VARSPLIC 332 341 IRGRERFEMF -> DGTSFQKENC (in isoform 2).
983
+ FT /FTId=VSP_006535.
984
+ FT VARSPLIC 342 393 Missing (in isoform 2).
985
+ FT /FTId=VSP_006536.
986
+ FT VARIANT 7 7 D -> H (in a skin tumor).
987
+ FT /FTId=VAR_005851.
988
+ FT VARIANT 35 35 L -> F (in a liver tumor).
989
+ FT /FTId=VAR_005852.
990
+ FT VARIANT 43 43 L -> S (in a renal tumor).
991
+ FT /FTId=VAR_005853.
992
+ FT VARIANT 47 47 P -> S (in dbSNP:1800371).
993
+ FT /FTId=VAR_014632.
994
+ FT VARIANT 53 53 W -> C (in a leukemia and a lymphoma).
995
+ FT /FTId=VAR_005854.
996
+ FT VARIANT 60 60 P -> S (in a leukemia and a lymphoma).
997
+ FT /FTId=VAR_005855.
998
+ FT VARIANT 72 72 P -> R (in dbSNP:1042522).
999
+ FT /FTId=VAR_005856.
1000
+ FT VARIANT 79 79 A -> T (in clone P53-H-1).
1001
+ FT /FTId=VAR_005857.
1002
+ FT VARIANT 87 87 P -> Q (in a brain tumor).
1003
+ FT /FTId=VAR_005858.
1004
+ FT VARIANT 94 94 S -> T (in a colon tumor).
1005
+ FT /FTId=VAR_005859.
1006
+ FT VARIANT 110 110 R -> C (in a liver and an uterus tumor).
1007
+ FT /FTId=VAR_005860.
1008
+ FT VARIANT 110 110 R -> L (in a liver tumor).
1009
+ FT /FTId=VAR_005861.
1010
+ FT VARIANT 110 110 R -> P (in a breast tumor).
1011
+ FT /FTId=VAR_005862.
1012
+ FT VARIANT 113 113 F -> C (in a lung tumor).
1013
+ FT /FTId=VAR_005863.
1014
+ FT VARIANT 125 125 T -> M (in a lung tumor).
1015
+ FT /FTId=VAR_005864.
1016
+ FT VARIANT 126 126 Y -> D (in a colorectal tumor).
1017
+ FT /FTId=VAR_005865.
1018
+ FT VARIANT 126 126 Y -> N (in a leukemia and a lymphoma).
1019
+ FT /FTId=VAR_005866.
1020
+ FT VARIANT 127 127 S -> F (in a lung tumor).
1021
+ FT /FTId=VAR_005867.
1022
+ FT VARIANT 128 128 P -> S (in a breast tumor).
1023
+ FT /FTId=VAR_005868.
1024
+ FT VARIANT 129 129 A -> D (in a sarcoma).
1025
+ FT /FTId=VAR_005869.
1026
+ FT VARIANT 130 130 L -> R (in a liver tumor).
1027
+ FT /FTId=VAR_005870.
1028
+ FT VARIANT 131 131 N -> K (in a colon tumor).
1029
+ FT /FTId=VAR_005872.
1030
+ FT VARIANT 131 131 N -> S (in a liver tumor).
1031
+ FT /FTId=VAR_005871.
1032
+ FT VARIANT 132 132 K -> M (in a sarcoma).
1033
+ FT /FTId=VAR_005873.
1034
+ FT VARIANT 132 132 K -> Q (in a breast tumor).
1035
+ FT /FTId=VAR_005874.
1036
+ FT VARIANT 133 133 M -> T (in LFS).
1037
+ FT /FTId=VAR_005875.
1038
+ FT VARIANT 135 135 C -> F (in a colon tumor).
1039
+ FT /FTId=VAR_005877.
1040
+ FT VARIANT 135 135 C -> S (in a colon tumor).
1041
+ FT /FTId=VAR_005876.
1042
+ FT VARIANT 136 136 Q -> E (in a breast tumor).
1043
+ FT /FTId=VAR_005878.
1044
+ FT VARIANT 136 136 Q -> K (in a colon tumor).
1045
+ FT /FTId=VAR_005879.
1046
+ FT VARIANT 137 137 L -> Q (in a liver tumor).
1047
+ FT /FTId=VAR_005880.
1048
+ FT VARIANT 138 138 A -> P (in a lung tumor).
1049
+ FT /FTId=VAR_005881.
1050
+ FT VARIANT 139 139 K -> N (in a breast, an ovary tumor, a
1051
+ FT leukemia and a lymphoma).
1052
+ FT /FTId=VAR_005882.
1053
+ FT VARIANT 140 140 T -> Y (in a leukemia and a lymphoma).
1054
+ FT /FTId=VAR_005883.
1055
+ FT VARIANT 141 141 C -> F (in a breast tumor).
1056
+ FT /FTId=VAR_005885.
1057
+ FT VARIANT 141 141 C -> G (in an ovary tumor).
1058
+ FT /FTId=VAR_005884.
1059
+ FT VARIANT 141 141 C -> Y (in many types of tumors).
1060
+ FT /FTId=VAR_005886.
1061
+ FT VARIANT 143 143 V -> A (in a colon tumor; strong DNA
1062
+ FT binding ability at 32.5 degrees Celsius;
1063
+ FT strong reduction of transcriptional
1064
+ FT activity at 37.5 degrees Celsius).
1065
+ FT /FTId=VAR_005887.
1066
+ FT VARIANT 144 144 Q -> P (in a leukemia and a lymphoma).
1067
+ FT /FTId=VAR_005888.
1068
+ FT VARIANT 145 145 L -> P (in a brain tumor).
1069
+ FT /FTId=VAR_005889.
1070
+ FT VARIANT 145 145 L -> Q (in an esophagus tumor).
1071
+ FT /FTId=VAR_005890.
1072
+ FT VARIANT 147 147 V -> D (in an ovary tumor).
1073
+ FT /FTId=VAR_005891.
1074
+ FT VARIANT 147 147 V -> G (in a prostate tumor).
1075
+ FT /FTId=VAR_005892.
1076
+ FT VARIANT 149 149 S -> P (in a breast tumor).
1077
+ FT /FTId=VAR_005893.
1078
+ FT VARIANT 151 151 P -> A (in a brain and a colon tumor).
1079
+ FT /FTId=VAR_005894.
1080
+ FT VARIANT 151 151 P -> S (in many types of tumors).
1081
+ FT /FTId=VAR_005895.
1082
+ FT VARIANT 151 151 P -> T (in a breast tumor).
1083
+ FT /FTId=VAR_005896.
1084
+ FT VARIANT 152 152 P -> L (in an esophagus tumor).
1085
+ FT /FTId=VAR_005897.
1086
+ FT VARIANT 152 152 P -> S (in oral squamous cell carcinoma).
1087
+ FT /FTId=VAR_005898.
1088
+ FT VARIANT 153 153 P -> T (in a colon tumor).
1089
+ FT /FTId=VAR_005899.
1090
+ FT VARIANT 154 154 G -> V (in esophagus tumor).
1091
+ FT /FTId=VAR_005900.
1092
+ FT VARIANT 155 155 T -> A (in an esophagus tumor).
1093
+ FT /FTId=VAR_005901.
1094
+ FT VARIANT 156 156 R -> P (in an osteosarcoma cell line).
1095
+ FT /FTId=VAR_005902.
1096
+ FT VARIANT 157 157 V -> D (in a liver tumor).
1097
+ FT /FTId=VAR_005903.
1098
+ FT VARIANT 157 157 V -> I (in colorectal carcinoma; from a
1099
+ FT patient with Turcot syndrome).
1100
+ FT /FTId=VAR_012977.
1101
+ FT VARIANT 157 157 V -> S (in a S. African hepatocellular
1102
+ FT carcinoma).
1103
+ FT /FTId=VAR_005904.
1104
+ FT VARIANT 158 158 R -> C (in a noninvasive head and neck
1105
+ FT tumor).
1106
+ FT /FTId=VAR_005905.
1107
+ FT VARIANT 158 158 R -> G (in a brain and a lung tumor).
1108
+ FT /FTId=VAR_005906.
1109
+ FT VARIANT 158 158 R -> H (in many types of tumors).
1110
+ FT /FTId=VAR_005907.
1111
+ FT VARIANT 160 160 M -> I (in a lung and a skin tumor).
1112
+ FT /FTId=VAR_005908.
1113
+ FT VARIANT 161 161 A -> S (in a brain tumor).
1114
+ FT /FTId=VAR_005909.
1115
+ FT VARIANT 162 162 I -> S (in a brain tumor).
1116
+ FT /FTId=VAR_005910.
1117
+ FT VARIANT 162 162 I -> V (in an ovary tumor).
1118
+ FT /FTId=VAR_005911.
1119
+ FT VARIANT 163 163 Y -> H (in HNSCC).
1120
+ FT /FTId=VAR_005912.
1121
+ FT VARIANT 164 164 K -> N (in a lung tumor).
1122
+ FT /FTId=VAR_005913.
1123
+ FT VARIANT 164 164 K -> Q (in a breast tumor).
1124
+ FT /FTId=VAR_005914.
1125
+ FT VARIANT 165 165 Q -> L (in a breast tumor).
1126
+ FT /FTId=VAR_005915.
1127
+ FT VARIANT 165 165 Q -> R (in an ovary tumor).
1128
+ FT /FTId=VAR_005916.
1129
+ FT VARIANT 166 166 S -> L (in a lung tumor).
1130
+ FT /FTId=VAR_005917.
1131
+ FT VARIANT 168 168 H -> R (in a brain tumor).
1132
+ FT /FTId=VAR_005918.
1133
+ FT VARIANT 169 169 M -> I (in oral squamous cell carcinoma).
1134
+ FT /FTId=VAR_005919.
1135
+ FT VARIANT 169 169 M -> T (in a noninvasive head and neck
1136
+ FT tumor).
1137
+ FT /FTId=VAR_005920.
1138
+ FT VARIANT 170 170 T -> M (in a colon tumor).
1139
+ FT /FTId=VAR_005921.
1140
+ FT VARIANT 170 170 T -> S (in a colon tumor).
1141
+ FT /FTId=VAR_005922.
1142
+ FT VARIANT 172 172 V -> A (in a prostate tumor).
1143
+ FT /FTId=VAR_005923.
1144
+ FT VARIANT 173 173 V -> E (in a colon tumor).
1145
+ FT /FTId=VAR_005924.
1146
+ FT VARIANT 173 173 V -> L (in a cervical carcinoma).
1147
+ FT /FTId=VAR_005925.
1148
+ FT VARIANT 173 173 V -> M (in a colon tumor).
1149
+ FT /FTId=VAR_005926.
1150
+ FT VARIANT 174 174 R -> H (in the cell line Detroit 562 of
1151
+ FT squamous cell carcinoma).
1152
+ FT /FTId=VAR_005927.
1153
+ FT VARIANT 175 175 R -> C (in a colon and an uterus tumor).
1154
+ FT /FTId=VAR_005928.
1155
+ FT VARIANT 175 175 R -> G (in a brain tumor).
1156
+ FT /FTId=VAR_005929.
1157
+ FT VARIANT 175 175 R -> H (in LFS and colon/esophagus/
1158
+ FT gastric tumors).
1159
+ FT /FTId=VAR_005932.
1160
+ FT VARIANT 175 175 R -> L (in a breast and a colon tumor).
1161
+ FT /FTId=VAR_005930.
1162
+ FT VARIANT 175 175 R -> P (in a cervical carcinoma).
1163
+ FT /FTId=VAR_005931.
1164
+ FT VARIANT 176 176 C -> F (in esophagus tumors and many
1165
+ FT types of tumors).
1166
+ FT /FTId=VAR_005933.
1167
+ FT VARIANT 176 176 C -> W (in a lung tumor).
1168
+ FT /FTId=VAR_005934.
1169
+ FT VARIANT 177 177 P -> L (in a skin tumor).
1170
+ FT /FTId=VAR_005935.
1171
+ FT VARIANT 178 178 H -> HPHP (in a Burkitt's lymphoma).
1172
+ FT /FTId=VAR_005936.
1173
+ FT VARIANT 181 181 R -> L (in a cervical carcinoma).
1174
+ FT /FTId=VAR_005937.
1175
+ FT VARIANT 182 182 C -> S (in a stomach tumor).
1176
+ FT /FTId=VAR_005938.
1177
+ FT VARIANT 184 184 D -> Y (in a leukemia and a lymphoma).
1178
+ FT /FTId=VAR_005939.
1179
+ FT VARIANT 186 186 D -> Y (in a breast tumor).
1180
+ FT /FTId=VAR_005940.
1181
+ FT VARIANT 187 187 G -> C (in a breast tumor).
1182
+ FT /FTId=VAR_005941.
1183
+ FT VARIANT 187 187 G -> S (in a leukemia and a lymphoma).
1184
+ FT /FTId=VAR_005942.
1185
+ FT VARIANT 189 189 A -> P (in an ovary tumor).
1186
+ FT /FTId=VAR_005943.
1187
+ FT VARIANT 190 190 P -> L (in a colorectal tumor).
1188
+ FT /FTId=VAR_005944.
1189
+ FT VARIANT 191 191 P -> T (in a colon tumor).
1190
+ FT /FTId=VAR_005945.
1191
+ FT VARIANT 192 192 Q -> R (in a colon tumor).
1192
+ FT /FTId=VAR_005946.
1193
+ FT VARIANT 193 193 H -> D (in an uterus tumor).
1194
+ FT /FTId=VAR_005947.
1195
+ FT VARIANT 193 193 H -> R (in LFS).
1196
+ FT /FTId=VAR_005948.
1197
+ FT VARIANT 194 194 L -> P (in a colon tumor).
1198
+ FT /FTId=VAR_005949.
1199
+ FT VARIANT 194 194 L -> R (in the cell line HU 281 of
1200
+ FT squamous cell carcinoma).
1201
+ FT /FTId=VAR_005950.
1202
+ FT VARIANT 195 195 I -> T (in oral squamous cell carcinoma).
1203
+ FT /FTId=VAR_005951.
1204
+ FT VARIANT 198 198 E -> K (in HNSCC).
1205
+ FT /FTId=VAR_005952.
1206
+ FT VARIANT 205 205 Y -> C (in oral squamous cell carcinoma).
1207
+ FT /FTId=VAR_005953.
1208
+ FT VARIANT 205 205 Y -> D (in HNSCC).
1209
+ FT /FTId=VAR_005954.
1210
+ FT VARIANT 213 213 R -> Q (in a Burkitt's lymphoma and a
1211
+ FT colorectal tumor).
1212
+ FT /FTId=VAR_005955.
1213
+ FT VARIANT 216 216 V -> M (in HNSCC).
1214
+ FT /FTId=VAR_005956.
1215
+ FT VARIANT 220 220 Y -> C (in oral squamous cell carcinoma).
1216
+ FT /FTId=VAR_005957.
1217
+ FT VARIANT 220 220 Y -> H (in a colon tumor).
1218
+ FT /FTId=VAR_005958.
1219
+ FT VARIANT 220 220 Y -> S (in HNSCC).
1220
+ FT /FTId=VAR_005959.
1221
+ FT VARIANT 228 228 D -> E (in HNSCC).
1222
+ FT /FTId=VAR_005960.
1223
+ FT VARIANT 230 230 T -> I (in oral squamous cell carcinoma).
1224
+ FT /FTId=VAR_005961.
1225
+ FT VARIANT 232 232 I -> T (in an anal tumor).
1226
+ FT /FTId=VAR_005962.
1227
+ FT VARIANT 234 234 Y -> C (in HNSCC).
1228
+ FT /FTId=VAR_005963.
1229
+ FT VARIANT 234 234 Y -> H (in a Burkitt's lymphoma).
1230
+ FT /FTId=VAR_005964.
1231
+ FT VARIANT 237 237 M -> I (in a colon tumor).
1232
+ FT /FTId=VAR_005965.
1233
+ FT VARIANT 238 238 C -> F (in an anal tumor).
1234
+ FT /FTId=VAR_005966.
1235
+ FT VARIANT 238 238 C -> Y (in a colorectal tumor).
1236
+ FT /FTId=VAR_005967.
1237
+ FT VARIANT 240 240 S -> I (in an anal tumor).
1238
+ FT /FTId=VAR_005968.
1239
+ FT VARIANT 241 241 S -> F (in a colon tumor).
1240
+ FT /FTId=VAR_005969.
1241
+ FT VARIANT 242 242 C -> F (in a skin tumor).
1242
+ FT /FTId=VAR_005970.
1243
+ FT VARIANT 245 245 G -> A (in a renal tumor).
1244
+ FT /FTId=VAR_005971.
1245
+ FT VARIANT 245 245 G -> C (in LFS, colon and larynx tumors).
1246
+ FT /FTId=VAR_005972.
1247
+ FT VARIANT 245 245 G -> D (in LFS and a colon tumor).
1248
+ FT /FTId=VAR_005973.
1249
+ FT VARIANT 245 245 G -> S (in esophageal adenocarcinoma and
1250
+ FT many types of tumors).
1251
+ FT /FTId=VAR_005974.
1252
+ FT VARIANT 245 245 G -> V (in HNSCC).
1253
+ FT /FTId=VAR_005975.
1254
+ FT VARIANT 246 246 M -> R (in a liver tumor).
1255
+ FT /FTId=VAR_005976.
1256
+ FT VARIANT 246 246 M -> T (in a leukemia and a lymphoma).
1257
+ FT /FTId=VAR_005977.
1258
+ FT VARIANT 246 246 M -> V (in many types of tumors).
1259
+ FT /FTId=VAR_005978.
1260
+ FT VARIANT 247 247 N -> I (in a lung tumor).
1261
+ FT /FTId=VAR_005980.
1262
+ FT VARIANT 247 247 N -> W (in a skin tumor).
1263
+ FT /FTId=VAR_005979.
1264
+ FT VARIANT 248 248 R -> G (in an endocrine tumor).
1265
+ FT /FTId=VAR_005981.
1266
+ FT VARIANT 248 248 R -> L (in tumors of hypopharynx, larynx
1267
+ FT and tonsil).
1268
+ FT /FTId=VAR_005982.
1269
+ FT VARIANT 248 248 R -> Q (in LFS and many types of tumors).
1270
+ FT /FTId=VAR_005983.
1271
+ FT VARIANT 248 248 R -> W (in LFS, esophageal adenocarcinoma
1272
+ FT and many types of tumors).
1273
+ FT /FTId=VAR_005984.
1274
+ FT VARIANT 249 249 R -> G (in a breast tumor).
1275
+ FT /FTId=VAR_005985.
1276
+ FT VARIANT 249 249 R -> S (in many types of tumors).
1277
+ FT /FTId=VAR_005986.
1278
+ FT VARIANT 251 251 I -> N (in HNSCC).
1279
+ FT /FTId=VAR_005987.
1280
+ FT VARIANT 252 252 L -> P (in LFS and many types of tumors).
1281
+ FT /FTId=VAR_005988.
1282
+ FT VARIANT 254 254 I -> N (in a breast tumor).
1283
+ FT /FTId=VAR_017908.
1284
+ FT VARIANT 254 254 I -> T (in a colon tumor).
1285
+ FT /FTId=VAR_017909.
1286
+ FT VARIANT 257 257 L -> P (in HNSCC).
1287
+ FT /FTId=VAR_005989.
1288
+ FT VARIANT 258 258 E -> D (in a colorectal tumor).
1289
+ FT /FTId=VAR_005990.
1290
+ FT VARIANT 258 258 E -> K (in LFS).
1291
+ FT /FTId=VAR_005991.
1292
+ FT VARIANT 272 272 V -> L (in LFS).
1293
+ FT /FTId=VAR_005992.
1294
+ FT VARIANT 273 273 R -> C (in LFS, colorectal tumor and oral
1295
+ FT squamous cell carcinoma).
1296
+ FT /FTId=VAR_005993.
1297
+ FT VARIANT 273 273 R -> G (in HNSCC).
1298
+ FT /FTId=VAR_005994.
1299
+ FT VARIANT 273 273 R -> H (in LFS, colon and esophagus
1300
+ FT tumors).
1301
+ FT /FTId=VAR_005995.
1302
+ FT VARIANT 274 274 V -> F (in a colorectal tumor).
1303
+ FT /FTId=VAR_005997.
1304
+ FT VARIANT 275 275 C -> W (in a breast and a stomach tumor).
1305
+ FT /FTId=VAR_005999.
1306
+ FT VARIANT 275 275 C -> Y (in LFS and tumors of brain, lung,
1307
+ FT kidney, stomach).
1308
+ FT /FTId=VAR_005998.
1309
+ FT VARIANT 277 277 C -> G (in a lung tumor).
1310
+ FT /FTId=VAR_006000.
1311
+ FT VARIANT 278 278 P -> A (in a breast tumor).
1312
+ FT /FTId=VAR_006001.
1313
+ FT VARIANT 278 278 P -> H (in a leukemia and a lymphoma).
1314
+ FT /FTId=VAR_006002.
1315
+ FT VARIANT 278 278 P -> L (in an esophagus and a lung
1316
+ FT tumor).
1317
+ FT /FTId=VAR_006003.
1318
+ FT VARIANT 278 278 P -> S (in oral squamous cell carcinoma).
1319
+ FT /FTId=VAR_006004.
1320
+ FT VARIANT 278 278 P -> T (in HNSCC; same patient as
1321
+ FT mutation His-281).
1322
+ FT /FTId=VAR_006005.
1323
+ FT VARIANT 279 279 G -> E (in a colorectal tumor).
1324
+ FT /FTId=VAR_006006.
1325
+ FT VARIANT 280 280 R -> I (in a colorectal tumor).
1326
+ FT /FTId=VAR_006008.
1327
+ FT VARIANT 280 280 R -> K (in a breast tumor).
1328
+ FT /FTId=VAR_006007.
1329
+ FT VARIANT 280 280 R -> T (in nasopharyngeal carcinoma).
1330
+ FT /FTId=VAR_006009.
1331
+ FT VARIANT 281 281 D -> A (in a leukemia and a lymphoma).
1332
+ FT /FTId=VAR_006010.
1333
+ FT VARIANT 281 281 D -> E (in many types of tumors).
1334
+ FT /FTId=VAR_006011.
1335
+ FT VARIANT 281 281 D -> G (in many types of tumors).
1336
+ FT /FTId=VAR_006012.
1337
+ FT VARIANT 281 281 D -> H (in HNSCC; same patient as
1338
+ FT mutation Thr-278).
1339
+ FT /FTId=VAR_006013.
1340
+ FT VARIANT 281 281 D -> V (in a colorectal tumor).
1341
+ FT /FTId=VAR_006014.
1342
+ FT VARIANT 282 282 R -> L (in a breast tumor).
1343
+ FT /FTId=VAR_006015.
1344
+ FT VARIANT 282 282 R -> W (in esophageal adenocarcinoma and
1345
+ FT many types of tumors).
1346
+ FT /FTId=VAR_006016.
1347
+ FT VARIANT 283 283 R -> C (in a colon tumor).
1348
+ FT /FTId=VAR_006017.
1349
+ FT VARIANT 283 283 R -> G (in a lung tumor).
1350
+ FT /FTId=VAR_006018.
1351
+ FT VARIANT 283 283 R -> H (in a colon tumor).
1352
+ FT /FTId=VAR_006019.
1353
+ FT VARIANT 283 283 R -> P (in a breast and a lung tumor).
1354
+ FT /FTId=VAR_006020.
1355
+ FT VARIANT 284 284 T -> A (in a colorectal tumor).
1356
+ FT /FTId=VAR_006021.
1357
+ FT VARIANT 284 284 T -> P (in a lung tumor).
1358
+ FT /FTId=VAR_006022.
1359
+ FT VARIANT 285 285 E -> K (in many types of tumors).
1360
+ FT /FTId=VAR_006023.
1361
+ FT VARIANT 285 285 E -> Q (in an uterus tumor).
1362
+ FT /FTId=VAR_006024.
1363
+ FT VARIANT 285 285 E -> V (in a liver tumor).
1364
+ FT /FTId=VAR_006025.
1365
+ FT VARIANT 286 286 E -> A (in LFS).
1366
+ FT /FTId=VAR_006026.
1367
+ FT VARIANT 286 286 E -> D (in a liver tumor).
1368
+ FT /FTId=VAR_006027.
1369
+ FT VARIANT 286 286 E -> G (in tumors of colon, lung, head
1370
+ FT and neck).
1371
+ FT /FTId=VAR_006028.
1372
+ FT VARIANT 286 286 E -> K (in many types of tumors).
1373
+ FT /FTId=VAR_006029.
1374
+ FT VARIANT 286 286 E -> Q (in esophageal adenocarcinoma).
1375
+ FT /FTId=VAR_006030.
1376
+ FT VARIANT 292 292 K -> I (in LFS).
1377
+ FT /FTId=VAR_015819.
1378
+ FT VARIANT 296 296 H -> P (in HNSCC).
1379
+ FT /FTId=VAR_006031.
1380
+ FT VARIANT 300 300 P -> R (in a skin tumor).
1381
+ FT /FTId=VAR_006032.
1382
+ FT VARIANT 301 301 P -> L (in a colon tumor).
1383
+ FT /FTId=VAR_006033.
1384
+ FT VARIANT 302 302 G -> E (in a colon tumor).
1385
+ FT /FTId=VAR_006034.
1386
+ FT VARIANT 302 302 G -> V (in a colon tumor).
1387
+ FT /FTId=VAR_006035.
1388
+ FT VARIANT 306 306 R -> Q (in a sarcoma).
1389
+ FT /FTId=VAR_006036.
1390
+ FT VARIANT 307 307 A -> T (in a breast tumor).
1391
+ FT /FTId=VAR_006037.
1392
+ FT VARIANT 309 309 P -> S (in a colon tumor).
1393
+ FT /FTId=VAR_006038.
1394
+ FT VARIANT 325 325 G -> V (in LFS).
1395
+ FT /FTId=VAR_006039.
1396
+ FT VARIANT 334 334 G -> V (in a lung tumor).
1397
+ FT /FTId=VAR_006040.
1398
+ FT VARIANT 337 337 R -> C (in LFS; nonclassical form; also
1399
+ FT found in a liver tumor).
1400
+ FT /FTId=VAR_006041.
1401
+ FT VARIANT 339 339 E -> K.
1402
+ FT /FTId=VAR_022316.
1403
+ FT VARIANT 366 366 S -> A.
1404
+ FT /FTId=VAR_022317.
1405
+ FT MUTAGEN 46 46 S->A: Abolishes phosphorylation by HIPK2
1406
+ FT and acetylation of K-382 by CREBBP.
1407
+ FT MUTAGEN 55 55 T->A: Blocks phosphorylation by TAF1.
1408
+ FT MUTAGEN 135 135 C->Y: Decreased E6-mediated binding to
1409
+ FT E6-AP.
1410
+ FT MUTAGEN 382 382 K->A: Abolishes acetylation by CREBBP.
1411
+ FT CONFLICT 76 76 A -> G (in Ref. 2; AAA59987).
1412
+ FT CONFLICT 155 155 T -> P (in Ref. 16).
1413
+ FT CONFLICT 254 254 I -> D (in Ref. 7; CAA42635).
1414
+ FT CONFLICT 262 262 G -> V (in Ref. 19).
1415
+ FT CONFLICT 282 282 R -> Q (in Ref. 18).
1416
+ FT STRAND 103 103
1417
+ FT HELIX 105 107
1418
+ FT TURN 108 108
1419
+ FT STRAND 110 112
1420
+ FT TURN 120 121
1421
+ FT STRAND 124 127
1422
+ FT TURN 128 131
1423
+ FT STRAND 132 135
1424
+ FT TURN 137 138
1425
+ FT STRAND 141 146
1426
+ FT TURN 153 154
1427
+ FT STRAND 156 163
1428
+ FT TURN 166 170
1429
+ FT HELIX 177 181
1430
+ FT TURN 191 192
1431
+ FT STRAND 195 197
1432
+ FT TURN 201 202
1433
+ FT STRAND 204 207
1434
+ FT TURN 209 211
1435
+ FT STRAND 214 219
1436
+ FT TURN 225 226
1437
+ FT STRAND 230 236
1438
+ FT TURN 240 241
1439
+ FT TURN 243 248
1440
+ FT STRAND 251 258
1441
+ FT TURN 260 261
1442
+ FT STRAND 264 274
1443
+ FT HELIX 278 286
1444
+ FT HELIX 335 354
1445
+ FT HELIX 376 378
1446
+ FT HELIX 379 384
1447
+ FT TURN 385 386
1448
+ SQ SEQUENCE 393 AA; 43653 MW; AD5C149FD8106131 CRC64;
1449
+ MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
1450
+ DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
1451
+ SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
1452
+ RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
1453
+ SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
1454
+ PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
1455
+ GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
1456
+ //